Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology sets up $125 million at-the-market stock sale program with TD Cowen

Neutral Impact 3 of 5 financing Written later

Nautilus Biotechnology entered a new Sales Agreement with TD Securities (USA), LLC (TD Cowen) that allows it to sell up to $125 million of common stock through an at-the-market offering, replacing a prior 2024 agreement with the same agent that the companies mutually terminated. The company has no obligation to sell any shares and can suspend sales at any time, but future sales would add new shares and dilute existing shareholders.

Key points

  • New Sales Agreement permits sales of up to $125,000,000 of common stock, to be issued under a shelf registration statement on Form S-3 once declared effective by the SEC.
  • TD Cowen would receive up to 3.0% of gross proceeds from any shares sold.
  • The prior Sales Agreement dated February 28, 2024 was mutually terminated on September 11, 2026; no shares were sold under it.
  • The company has no obligation to sell any shares and may suspend offers at any time.

The filing

CompanyNautilus Biotechnology, Inc. (NAUT)
Form8-K, current report
Filed with the SECSep 11, 2026, 4:08 PM ET
Accession number0001808805-26-000041

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.